Edmonton, Alberta, June 13, 2011 – Innovotech Inc. (TSX-V: IOT), a pioneer in the field of biofilm product development, today announced that it has received its first purchase order for InnovoSCEPT™ veterinary biofilm susceptibility tests for launch into the Japanese veterinary market. The Company anticipates expansion to the balance of the worldwide veterinary market to follow quickly.
“This initial order of InnovoSCEPT™ veterinary tests provides a new and improved method to identify effective treatments for chronic infections in animals. The situation in the animal world parallels what is seen in human health, where inappropriate treatment of chronic infections results in unnecessary patient suffering, repeated treatment failures, increased health care costs and an increase in the potential for bacterial resistance,” said Ken Boutilier, President and CEO of Innovotech. “Our company has developed the InnovoSCEPT™ line of five new products for susceptibility testing in both humans and animals in less than six months. This initial purchase order for introduction into the Japanese market is just the start of what should become an important revenue generator.”
The InnovoSCEPT™ line of veterinary tests, based on the technology used to develop Innovotech’s bioFILM PA™ human susceptibility test, will assist veterinarians in the selection of the most effective antibiotic treatment of infections caused by both gram-positive and gram-negative bacteria in both small and large animals. As with human infections, many common disease-causing bacteria exist in animals as biofilms, such as those responsible for infections causing mastitis in dairy cows or persistent skin infections in family pets. These chronic infections are often difficult to eradicate and Innovotech’s tests have a much better chance of being successful in the identification of the best treatment approach in comparison to current methods.
Biofilms are organized communities of microorganisms that exist in virtually every natural environment. Biofilms can be up to 1000 times more resistant to treatment than the same organism in a free-floating state.
About Innovotech Inc.
Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are responsible for a host of diseases both in human health and agriculture due to their inherent resistance to existing antibiotics and disinfectants. Aside from Innovotech’s products there are no antibiotics, disinfectants, diagnostics or regulatory standards designed specifically for biofilm-forming organisms.
Innovotech has a broad range of products that address the issue of biofilms within a number of different industries, including three commercial products, the MBEC Assay™, bioFILM PA™ and InnovoSCEPT™ veterinary kits. The MBEC Assay™ is a high throughput biofilm growth device that was recently approved as an ASTM International standard. bioFILM PA™ is the first diagnostic kit to assist physicians in the selection of the most effective combination antibiotic treatment of patients with biofilm-based chronic lung infections, while the InnovoSCEPT™ veterinary kits are designed to determine the most effective antibiotic treatment for infections in both large and small animals.
Innovotech also has two products in advanced stages of development; Agress® is a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections and Sani-Lux™ is a light-activated, natural hard surface sanitizer.
For more information contact:
Ken Boutilier, President and CEO
Phone: (780) 448-0585 ext. 221
Fax: (780) 424-0941
Amanda Stadel, Communications Officer
Phone: (780) 448-0585 ext. 224
Fax: (780) 424-0941
Connect with us: